Palvella Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 |
|---|---|---|
Revenue | $0 | $0 |
EBITDA | -8,117 | -6,970 |
EBIT | -9,250 | -7,871 |
Net Income | -9,471 | -8,185 |
Net Change In Cash | 0 | 0 |
Free Cash Flow | -5,434 | -6,768 |
Cash | 70,433 | 75,626 |
Basic Shares | 11,052 | 2,226 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $25,902 | $31,418 |
Gross Profit | 23,122 | 29,050 | ||
EBITDA | -13,117 | 18,691 | -30,497 | -43,370 |
EBIT | -14,095 | -11,869 | -33,277 | -45,738 |
Net Income | -17,434 | 18,691 | -33,277 | -45,738 |
Net Change In Cash | 0 | 0 | 25,902 | 31,418 |
Free Cash Flow | -10,840 | -13,703 | -14,840 | -8,609 |
Cash | 83,602 | 7,350 | 16,053 | 117,764 |
Basic Shares | 2,226 | 1,268 | 930 | 806 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.85 |
2025-03-31 | -$0.74 |
2024-09-30 | -$2.18 |
2024-06-30 | -$2.76 |
